<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00216398</url>
  </required_header>
  <id_info>
    <org_study_id>A-9B-52030-159</org_study_id>
    <nct_id>NCT00216398</nct_id>
  </id_info>
  <brief_title>Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR</brief_title>
  <official_title>A Phase IV, Multicentre, Open-Label, Single Group Study to Evaluate the Dosing, Efficacy and Safety of Lanreotide Autogel in Patients With Acromegaly Previously Treated With Octreotide LAR</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the efficacy, safety and patient acceptability of
      Somatuline Autogel in patients with acromegaly previously treated with octreotide LAR.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>June 2004</start_date>
  <completion_date>December 2006</completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>The percentage of patients with GH control (&lt;5.0 mU.L) and normalised IGF-1 at week 44 compared to the baseline (Week 0) visit.</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients with GH control (&lt; 5.0 mU/L) at each visit to week 44 compared to the baseline (Week 0) visit.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The percentage of patients with normalised IGF-1 compared to the baseline visit.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the GH values compared to the baseline (Week 0) visit.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the IGF-1 values compared to the baseline (Week 0) visit.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in serum lanreotide levels compared to the baseline (Week 0) visit.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in the serum octreotide levels compared to the baseline visit.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Patient evaluation of lanreotide Autogel treatment compared with evaluation of octreotide LAR treatment.</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator evaluation of lanreotide Autogel treatment compared with evaluation of octreotide LAR treatment.</measure>
  </secondary_outcome>
  <enrollment>8</enrollment>
  <condition>Acromegaly</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lanreotide (Autogel formulation)</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Clinical diagnosis of acromegaly

          -  The patient must have been tested at Week -4 (4 weeks prior to the Baseline visit) and
             shown to have a GH level &lt;10 mU/L.

          -  The patient must have been treated with a stable dose of octreotide LAR for at least
             four months prior to study entry

          -  Life expectancy of at least 2 years

        Exclusion Criteria:

          -  Adenectomy within past 6 months, or likely during study period

          -  Radiotherapy for acromegalic disease within 1 year, or likely during study period

          -  Unstable concomitant dopamine agonist therapy
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Hugues Berard, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <zip>2145</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
  </location_countries>
  <verification_date>October 2007</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 20, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 22, 2005</study_first_posted>
  <last_update_submitted>October 11, 2007</last_update_submitted>
  <last_update_submitted_qc>October 11, 2007</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 12, 2007</last_update_posted>
  <keyword>acromegaly</keyword>
  <keyword>growth hormone</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acromegaly</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Octreotide</mesh_term>
    <mesh_term>Lanreotide</mesh_term>
    <mesh_term>Angiopeptin</mesh_term>
    <mesh_term>Somatostatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

